Biren Amin
Stock Analyst at Piper Sandler
(1.14)
# 3,474
Out of 4,784 analysts
54
Total ratings
35.42%
Success rate
-15.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Downgrades: Neutral | $10 → $0.7 | $0.26 | +169.23% | 2 | Mar 21, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $40.33 | +88.45% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $1.99 | +503.02% | 1 | Feb 19, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $74 → $71 | $25.65 | +176.80% | 2 | Feb 6, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Neutral | $34 → $4 | $4.18 | -4.31% | 3 | Jan 30, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Overweight | $35 | $5.52 | +534.06% | 1 | Dec 2, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $200 → $182 | $70.41 | +158.49% | 5 | Nov 27, 2024 | |
| IMNM Immunome | Maintains: Overweight | $23 → $21 | $6.99 | +200.43% | 3 | Nov 14, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $11 → $9 | $1.55 | +480.65% | 2 | Nov 14, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $91 → $115 | $67.96 | +69.22% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $24.27 | +31.85% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $46 | $35.11 | +31.02% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $1.60 | +87.50% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.32 | +362.96% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.58 | +97.89% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.81 | +3,767.40% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.37 | +13,561.93% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $6.67 | +259.82% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.93 | +1,661.66% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $6.05 | +8,164.46% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $4.63 | +202.38% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $637.36 | +8.42% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $0.63 | +1,491.85% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.08 | - | 4 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $18.95 | +432.98% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $113.16 | -39.02% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $492.69 | -68.54% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.81 | +7,413.81% | 4 | Mar 6, 2017 |
Elevation Oncology
Mar 21, 2025
Downgrades: Neutral
Price Target: $10 → $0.7
Current: $0.26
Upside: +169.23%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $40.33
Upside: +88.45%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $1.99
Upside: +503.02%
Viking Therapeutics
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $25.65
Upside: +176.80%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.18
Upside: -4.31%
Corbus Pharmaceuticals Holdings
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $5.52
Upside: +534.06%
Sarepta Therapeutics
Nov 27, 2024
Maintains: Overweight
Price Target: $200 → $182
Current: $70.41
Upside: +158.49%
Immunome
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $6.99
Upside: +200.43%
Allogene Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $11 → $9
Current: $1.55
Upside: +480.65%
Arcellx
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $67.96
Upside: +69.22%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $24.27
Upside: +31.85%
Sep 4, 2024
Initiates: Overweight
Price Target: $46
Current: $35.11
Upside: +31.02%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $1.60
Upside: +87.50%
Jun 21, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.32
Upside: +362.96%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $7.58
Upside: +97.89%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.81
Upside: +3,767.40%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.37
Upside: +13,561.93%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $6.67
Upside: +259.82%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $1.93
Upside: +1,661.66%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $6.05
Upside: +8,164.46%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $4.63
Upside: +202.38%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $637.36
Upside: +8.42%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $0.63
Upside: +1,491.85%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.08
Upside: -
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $18.95
Upside: +432.98%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $113.16
Upside: -39.02%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $492.69
Upside: -68.54%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.81
Upside: +7,413.81%